References
- Yildiz BO, Bozdag G, Yapici Z, et al. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 2012;27:3067–73.
- Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocr Metab 2013;98:4565–92.
- Galluzzo A, Amato MC, Giordano C. Insulin resistance and polycystic ovary syndrome. Nutr Metab Cardiovasc Dis 2008;18:511–8.
- Amato MC, Vesco R, Vigneri E, et al. Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance. J Endocrinol Invest 2015;38:1319–26.
- Amato MC, Magistro A, Gambino G, et al. Visceral adiposity index and DHEAS are useful markers of diabetes risk in women with polycystic ovary syndrome. Eur J Endocrinol 2015;172:79–88.
- Amato MC, Giordano C, Galia M, AlkaMeSy Study Group, et al. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010;33:920–2.
- Lindholm A, Andersson L, Eliasson M, et al. Prevalence of symptoms associated with polycystic ovary syndrome. Int J Gynaecol Obstet 2008;102:39–43.
- Xu N, Azziz R, Goodarzi M. Epigenetics in polycystic ovary syndrome: a pilot study of global dna methylation. Fertil Steril 2010; 94:781–3.e1.
- Welt CK, Carmina E. Life cycle of polycystic ovary syndrome(PCOS): from in utero to menopause. J Clin Endocrinol Metab 2013;98:4629–38.
- Eriksen MB, Nielsen MFB, Brusgaard K, et al. Genetic alterations within the DENND1A gene in patients with polycystic ovary syndrome (PCOS). PLoS One 2013;8:e77186.
- Ilie IR, Georgescu CE. Polycystic ovary syndrome-epigenetic mechanisms and aberrant microRNA. Adv Clin Chem 2015;71:25–45.
- Bartel D. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281–97.
- Esquela-Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259–69.
- Osmai M, Osmai Y, Bang-Berthelsen CH, et al. MicroRNAs as regulators of beta-cell function and dysfunction. Diabetes Metab Res Rev 2016;32:334–49.
- Xu J, Zhao J, Evan G, et al. Circulating microRNAs: novel biomarkers for cardiovascular diseases. J Mol Med (Berl) 2012;90:865–75.
- Heneghan HM, Miller N, Kerin MJ. Role of microRNAs in obesity and the metabolic syndrome. Obes Rev 2010;11:354–61.
- Wei S, Xu H, Kuang Y. Systematic enrichment analysis of microRNA expression profiling studies in endometriosis. Iran J Basic Med Sci 2015;18:423–9.
- Ranjha R, Paul J. Micro-RNAs in inflammatory diseases and as a link between inflammation and cancer. Inflamm Res 2013;62:343–55.
- Murri M, Insenser M, Ferna´ndez-Dura´n E, San-Milla´n JL, Escobar-Morreale HF, Effects of polycystic ovary syndrome (PCOS), sex hormones, and obesity on circulating miRNA-21, miRNA-27b, miRNA-103, and miRNA-155 expression. J Clin Endocr Metab 2013;98:E1835–44.
- Long W, Zhao C, Ji C, et al. Characterization of serum microRNAs profile of PCOS and identification of novel non-invasive biomarkers. Cell Physiol Biochem 2014;33:1304–15.
- Zhang H, Jiang X, Zhang Y, et al. MicroRNA 376a regulates follicle assembly by targeting pcna in fetal and neonatal mouse ovaries. Reproduction 2014;148:43–54.
- Sirotkin AV, Laukov M, Ovcharenko D, et al. Identification of microRNAs controlling human ovarian cell proliferation and apoptosis. J Cell Physiol 2010;223:49–56.
- Roth LW, McCallie B, Alvero R, et al. Altered microRNA and gene expression in the follicular fluid of women with polycystic ovary syndrome. J Assist Reprod Genet 2014;31:355–62.
- McCallie B, Schoolcraft WB, Katz-Jaffe MG. Aberration of blastocyst microRNA expression is associated with human infertility. Fertil Steril 2010;93:2374–82.
- Trajkovski M, Hausser J, Soutschek J, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 2011;474:649–53.
- ChenY H, Heneidi S, Lee J-M, et al. MiRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance. Diabetes 2013;62:2278–86.
- Sørensen AE, Wissing ML, Salö S, et al. MicroRNAs related to polycystic ovary syndrome (PCOS). Genes (Basel) 2014;5:684–708.
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25.
- Amato MC, Verghi M, Galluzzo A, Giordano C. The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. Hum Reprod 2011;26:1486–94.
- Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocr Metab 1961;21:1440–7.
- Utzschneider KM, Prigeon RL, Faulenbach MV, et al. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 2009;32:335–41.
- Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462–70.
- DeFronzo RA, Matsuda M. Reduced time points to calculate the composite index. Diabetes Care 2010;33:e93.
- Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
- Diamanti-Kandarakis E, Mitrakou A, Hennes MM, et al. Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism 1995;44:525–31.
- Carletti MZ, Fiedler SD, Christenson LK. MicroRNA 21 blocks apoptosis in mouse periovulatory granulosa cells. Biol Reprod 2010;83:286–95.
- Ding C-F, Chen W-Q, ZhuY T, et al. Circulating microRNAs in patients with polycystic ovary syndrome. Hum Fertil 2015;18:22–9.
- Ferna´ndez-Hernando C, Sua´rez Y, Rayner KJ, Moore KJ, MicroRNAs in lipid metabolism. Curr Opin Lipidol 2011;22:86–92.
- Aranda JF, Madrigal-Matute J, Rotllan N, Ferna´ndez-Hernando C. MicroRNA modulation of lipid metabolism and oxidative stress in cardiometabolic diseases. Free Radical Bio Med 2013;64:31–9.
- Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective cardiovascular Münster study. Am J Cardiol 1992;70:733–7.